Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

CARA has been the subject of a number of other research reports. Canaccord Genuity Group lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $10.00 to $1.00 in a research report on Thursday, June 13th. Canaccord Genuity Group reiterated a “hold” rating and issued a $1.00 price objective (down from $10.00) on shares of Cara Therapeutics in a report on Thursday, June 13th. Needham & Company LLC cut Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 13th. Stifel Nicolaus lowered Cara Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $6.00 to $1.00 in a research note on Thursday, June 13th. Finally, HC Wainwright cut Cara Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. Based on data from MarketBeat, Cara Therapeutics has an average rating of “Hold” and an average price target of $2.32.

Cara Therapeutics Stock Performance

CARA opened at $0.28 on Friday. The business’s 50 day moving average is $0.32 and its 200-day moving average is $0.50. The stock has a market cap of $15.07 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.68.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, analysts forecast that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Cara Therapeutics

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN grew its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN owned about 3.54% of Cara Therapeutics worth $499,000 as of its most recent SEC filing. Institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.